Alliance Foundation Trials
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Alliance Foundation Trials sits in the top decile of US sponsors by registered trial count (#743 of 15,742 sponsors by registered trial count).
Alliance Foundation Trials: 20 sponsored US clinical trials, 3 recruiting.
Alliance Foundation Trials sponsors 20 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 6 completed. 3 of these trials are in Phase 3-4 (later-stage) and 13 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Blood Clot, with 1 trials.
Top-decile sponsor footprint
Alliance Foundation Trials ranks in the top decile of sponsors by registered trial count (#743 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
20 total, page 1 of 1
Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer
NCT07149363
Longitudinal Screening for Financial Hardship to Improve Outcomes in Patients With Advanced Cancer
NCT06963723
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
NCT04486352
Atezolizumab Immunotherapy With or Without Tiragolumab for Patients With Unresectable Stage III NSCLC
NCT05798663
Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide
NCT04335682
CHIO3 Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer
NCT04062708
Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM
NCT04009109
Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma
NCT03478514
Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer
NCT02947685
Comparing an Operation to Monitoring, With or Without Endocrine Therapy (COMET) Trial For Low Risk DCIS
NCT02926911
PALbociclib CoLlaborative Adjuvant Study
NCT02513394
Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma
NCT03702725
Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease
NCT03656627
Atezolizumab Immunotherapy in Patients With Advanced NSCLC
NCT03102242
Electronic Patient Reporting of Symptoms During Cancer Treatment
NCT03249090
Pembrolizumab vs Topotecan in Patients With Small Cell Lung Cancer
NCT02963090
A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer
NCT03009981
Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer
NCT02744092
A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer
NCT02967133
Optimal Sequencing of Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in First-Line NSCLC
NCT02591615
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 10 |
| Phase 3 | 3 |
Therapeutic Areas
What is open in the Alliance Foundation Trials pipeline
3 recruiting of 20 indexed (15% open); 6 completed (30%).
Phase mix: 3 late (III/IV) vs 13 early (I/II) (early-phase heavy).
Top condition: Blood Clot (1 trial), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Alliance Foundation Trials: open-pipeline peers nationwide
Peers matched on 20 registered trials and 15% open enrollment, not the therapeutic-area sidebar.
Alliance Foundation Trials sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 20 trials (± recruiting share)
- 59th Medical Wing · 20 trials · 15% recruiting
- Abiomed · 20 trials · 10% recruiting
- Agency for Healthcare Research and Quality (AHRQ) · 20 trials · 0% recruiting
- Applied Science & Performance Institute · 20 trials · 0% recruiting
Sponsors near 15% open enrollment (± trial volume)
- Hoag Memorial Hospital Presbyterian · 15% recruiting · 20 trials
- Medtronic Neurovascular Clinical Affairs · 15% recruiting · 20 trials
- Vivek Reddy · 15% recruiting · 20 trials
- Georgetown University · 15% recruiting · 227 trials
Related
What to do with this Alliance Foundation Trials page
20 registered trials is a research-attention snapshot, not an endorsement of Alliance Foundation Trials or any single study.
- 3 of Alliance Foundation Trials's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Blood Clot is the condition Alliance Foundation Trials studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Blood Clot trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Alliance Foundation Trials pipeline card: 20 registered trials from official public datasets.Report a data error.